| Applied Molecular Transport is a clinical-stage biopharmaceutical company utilizing its proprietary technology platform to design and develop a pipeline of oral and respiratory biologic product candidates to treat autoimmune, inflammatory, metabolic, and other diseases. Co. has two oral biologics in clinical development. Co.'s product candidate, AMT-101, is in Phase 2 development for patients with ulcerative colitis and related inflammatory indications. Co.'s second product candidate, AMT-126 is in Phase 1 development for diseases related to intestinal epithelium barrier function defects. The AMTI YTD return is shown above.
The YTD Return on the AMTI YTD return page and across the coverage universe of our site,
is a measure of the total return for a given investment year-to-date for the current calendar year
(up to the end of prior trading session). Arguably, choosing the current calendar year for a measurement
period is on the one hand completely arbitrary, but on the other hand a year-to-date look can be extremely
useful in the context of our country's tax system which taxes gains and income on a calendar year basis.
Thus, researching Year-To-Date Returns is good practice for investors — whether AMTI YTD return or other benchmarks/peers
— and when doing so it is also important to factor in dividends, because a financial instrument's YTD return is
more than just the change in price if that instrument pays a dividend or coupon. Our website aims to empower investors
by performing the AMTI YTD return calculation (with any dividends reinvested as applicable), and to provide a
coverage universe of many stocks and ETFs to be able to compare YTD returns.